Recent News

• 05.27.2025 - LENZ Therapeutics to Present at Upcoming Investor Conferences
• 05.09.2025 - LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia
• 05.07.2025 - LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
• 05.06.2025 - LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference
• 04.30.2025 - LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025

Recent Filings

• 05.09.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 05.07.2025 - 8-K Current report
• 05.07.2025 - EX-99.1 EX-99.1
• 05.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 04.28.2025 - DEF 14A Other definitive proxy statements
• 04.28.2025 - ARS Annual Report to Security Holders
• 04.28.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.15.2025 - 8-K Current report
• 04.14.2025 - EFFECT Notice of Effectiveness
• 04.14.2025 - EFFECT Notice of Effectiveness